Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 149 | 32 | 113 |
| Samples | 142 | 32 | 107 |
| Peptides | 115 | 23 | 89 |
Function
FBXW4 · F-box and WD repeat domain containing 4
This gene is a member of the F-box/WD-40 gene family, which recruit specific target proteins through their WD-40 protein-protein binding domains for ubiquitin mediated degradation. In mouse, a highly similar protein is thought to be responsible for maintaining the apical ectodermal ridge of developing limb buds; disruption of the mouse gene results in the absence of central digits, underdeveloped or absent metacarpal/metatarsal bones and syndactyly. This phenotype is remarkably similar to split hand-split foot malformation in humans, a clinically heterogeneous condition with a variety of modes of transmission. An autosomal recessive form has been mapped to the chromosomal region where this gene is located, and complex rearrangements involving duplications of this gene and others have been associated with the condition. A pseudogene of this locus has been mapped to one of the introns of the BCR gene on chromosome 22. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000664783 | P57775 | 123 | 99 |
| ENST00000331272 | A0A5F9UQ55* | 26 | 23 |
Gene Properties
Recurrent Mutations
All 99 amino-acid changes on canonical ENST00000664783 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in FBXW4 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in FBXW4 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Osteosarcoma | 3/45 7% | 0/166 0% |
| Endometrial Carcinoma | 2/42 5% | 4/612 1% |
| Burkitts Lymphoma | 0/32 0% | 2/196 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 4/810 0% |
| Colorectal Carcinoma | 4/143 3% | 19/3239 1% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 7/1390 0% |
| Gastric Carcinoma | 0/74 0% | 9/1809 0% |
| Melanoma | 3/210 1% | 7/1899 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Bladder Carcinoma | 1/58 2% | 3/956 0% |
| Esophageal Carcinoma | 0/23 0% | 3/769 0% |
| Other Solid Cancers | 0/94 0% | 6/1515 0% |
| Hepatocellular Carcinoma | 0/46 0% | 7/2210 0% |
| Glioma | 0/52 0% | 6/2127 0% |
| Ovarian Carcinoma | 2/109 2% | 1/998 0% |
| Small Cell Lung Carcinoma | 1/9 11% | 1/752 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 4/1592 0% |
| B-Cell Non-Hodgkins Lymphoma | 4/88 5% | 2/2534 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
| B-Lymphoblastic Leukemia | 2/55 4% | 2/2640 0% |
| Other Blood Cancers | 1/61 2% | 3/2725 0% |
| Prostate Carcinoma | 0/13 0% | 3/2105 0% |
| Neuroblastoma | 1/87 1% | 1/1331 0% |
| Neuroendocrine Tumour | 0/154 0% | 1/577 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 3/2550 0% |
| Head and Neck Carcinoma | 0/85 0% | 2/1574 0% |
| Biliary Tract Carcinoma | 0/54 0% | 1/950 0% |
| Kidney Carcinoma | 1/85 1% | 1/1862 0% |
Mutation Distribution
Where FBXW4 is mutated · all tissues, split by cell line vs tissue
How many mutations in FBXW4 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 149 mutations in FBXW4
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|